Skip to Content

BioCryst Pharmaceuticals, Inc. is sold by the State of New Jersey Common Pension Fund D for 84,298 shares (NASDAQ:BCRX)

BioCryst Pharmaceuticals, Inc. is sold by the State of New Jersey Common Pension Fund D for 84,298 shares (NASDAQ:BCRX)

The most recent Form 13F filing that the company made with the SEC revealed that during the third quarter of 2018, the State of New Jersey Common Pension Fund D reduced its holdings in BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) by 33.8%. The institutional investor now has 165,341 shares of the biotechnology company’s stock after selling 84,298 shares during the quarter. This brings the total number of shares of the company’s stock that they own to 165,341. At the end of the most recent reporting period, the State of New Jersey Common Pension Fund D owned approximately 0.09% of BioCryst Pharmaceuticals. This information was obtained from the fund’s most recent filing. At the time, this stake was estimated to be worth $2,083,000.

Throughout the past few months, a wide variety of other institutional investors have engaged in transactions that included the buying and selling shares of stock in the company. Shares of BioCryst Pharmaceuticals were purchased by Fairfield Bush & Co. for a total investment amount of $34,000 during the first three months of the year. During the first three months of 2018, Lazard Asset Management LLC spent $57,000 on new investments in BioCryst Pharmaceuticals. The company made this investment. During the second quarter, Amundi made an initial investment of $86,000 in BioCryst Pharmaceuticals, establishing a new position in the company. InterOcean Capital Group LLC made a new holding investment in BioCryst Pharmaceuticals during the second quarter, worth a total of $106,000. The investment was made in the company’s common stock. During the second quarter, Xponance Inc. established a new holding consisting of BioCryst Pharmaceuticals shares with a total value of 107,000 dollars. Institutional investors own the company’s stock 79.05 percent, and these investors have invested in the company.

The stock in question has been the subject of discussion in recent comments made by several market analysts. Barclays announced in a research note published on Friday, December 16th, that they would be lowering their price target on BioCryst Pharmaceuticals shares from $12.00 to $10.00. The new price target is intended to reflect Barclays’ expectation that the stock price will move lower. The first day that information was made available on shares of BioCryst Pharmaceuticals on StockNews.com was on Wednesday, October 12th. They advised their clients to “hold” the stock moving forward. In a research report released on November 2nd, Evercore ISI announced that they were increasing their price target on BioCryst Pharmaceuticals from $14.00 to $16.00 and upgrading the stock from an “in-line” rating to an “outperform” rating. Both of these changes were made to the company’s stock. Last but not least, in a report dated November 2nd, Royal Bank of Canada lowered their “sector performed” rating on BioCryst Pharmaceuticals shares and lowered their price objective on the stock from $14.00 to $13.00. Both of these changes were made in response to recent market developments. Three equity research analysts have provided the stock with a buy rating, while six have provided the stock with a hold recommendation. The stock

Tags

Leave a comment

Your email address will not be published. Required fields are marked *